[1]陈 丽,郝丽娟.多囊卵巢综合征患者腹型肥胖、高雄、胰岛素抵抗及脂代谢的相关性分析[J].医学信息,2022,35(12):113-117.[doi:10.3969/j.issn.1006-1959.2022.12.027]
 CHEN Li,HAO Li-juan.Correlation of Abdominal Obesity, Hyperandrogenism, Insulin Resistance and Lipid Metabolism in Patients with Polycystic Ovary Syndrome[J].Medical Information,2022,35(12):113-117.[doi:10.3969/j.issn.1006-1959.2022.12.027]
点击复制

多囊卵巢综合征患者腹型肥胖、高雄、胰岛素抵抗及脂代谢的相关性分析()
分享到:

医学信息[ISSN:1006-1959/CN:61-1278/R]

卷:
35卷
期数:
2022年12期
页码:
113-117
栏目:
论著
出版日期:
2022-06-15

文章信息/Info

Title:
Correlation of Abdominal Obesity, Hyperandrogenism, Insulin Resistance and Lipid Metabolism in Patients with Polycystic Ovary Syndrome
文章编号:
1006-1959(2022)12-0113-05
作者:
陈 丽郝丽娟
(重庆医科大学附属妇女儿童医院妇产科,重庆 401147)
Author(s):
CHEN LiHAO Li-juan
(Department of Obstetrics and Gynecology,Women and Children’s Hospital of Chongqing Medical University,Chongqing 401147,China)
关键词:
多囊卵巢综合征腹型肥胖高雄脂代谢异常胰岛素抵抗腰围
Keywords:
Polycystic ovary syndromeAbdominal obesityhyperandrogenismLipid metabolism disorderInsulin resistanceWaist circumference
分类号:
R711.75
DOI:
10.3969/j.issn.1006-1959.2022.12.027
文献标志码:
A
摘要:
目的 探讨多囊卵巢综合征(PCOS)患者腹型肥胖、高雄(临床高雄和生化高雄)与胰岛素抵抗(IR)及脂代谢的相关性。方法 回顾性分析2018年1月-10月我院收治的143例PCOS患者临床资料,根据不同肥胖标准分为腹型肥胖组与非腹型肥胖组、整体肥胖组与非整体肥胖组,另根据不同高雄标准分为临床高雄组与非临床高雄组、生化高雄组与非生化高雄组,分析不同标准下的肥胖率及高雄率,肥胖与高雄、IR及脂代谢的关系,高雄与肥胖、IR及血脂指标的关系。结果 纳入的143例PCOS患者中,整体肥胖率为31.47%,腹型肥胖率为48.25%,总IR率为58.74%,总高雄率为85.31%,其中临床高雄率为80.42%,生化高雄率为40.56%。腹型肥胖组与非腹型肥胖组T、TC、TG、HDL-C、HOMA-IR比较,差异有统计学意义(P<0.05),而两组mF-G评分、LDL-C比较,差异无统计学意义(P>0.05);整体肥胖组与非整体肥胖组TC、TG、HDL-C、HOMA-IR比较,差异有统计学意义(P<0.05),而两组T、mF-G评分、LDL-C比较,差异无统计学意义(P>0.05);Pearson相关分析显示,WC和BMI与HOMA-IR、TC、TG呈正相关,与HDL-C呈负相关(P<0.05);二者均与LDL-C无相关性(P>0.05);临床高雄组与非临床高雄组及生化高雄组与非生化高雄组肥胖指标、HOMA-IR及脂代谢指标比较,差异无统计学意义(P>0.05);多因素Logistic分析显示,不论是否存在肥胖或是IR均与生化高雄和临床高雄无相关性,血脂相关指标亦与高雄无明显相关性(P>0.05)。结论 PCOS患者主要表现为腹型肥胖,且腹型肥胖患者更易发生糖脂代谢紊乱。临床高雄与生化高雄在诊断PCOS具有同等效力,且不论是否存在高雄,均应重视IR及脂代谢异常,以提高对PCOS患者的诊疗预后。
Abstract:
Objective To investigate the relationship between abdominal obesity, hyperandrogenism, insulin resistance (IR) and lipid metabolism in patients with polycystic ovary syndrome (PCOS).Methods A total of 143 patients with PCOS treated in our hospital from January to October 2018 were analyzed. Patients were divided into abdominal obesity group and non-abdominal obesity group, overall obesity group and non-overall obesity group according to different obesity standards. In addition, they were divided into clinical hyperandrogenism group and non-clinical hyperandrogenism group, biochemical hyperandrogenism group and non-biochemical hyperandrogenism group by different hyperandrogenism standards. The obesity rate and hyperandrogenism rate were analyzed under different standards. The relationship between obesity and hyperandrogenism, IR and lipid metabolism, as well as hyperandrogenism and obesity, IR and lipid index were analyzed.Results Among 143 patients with PCOS, the overall obesity rate was 31.47%, and abdominal obesity rate was 48.25%, the total IR rate was 58.74%, the total hyperandrogenism rate was 85.31%, while clinical hyperandrogenism rate was 80.42% and the biochemical hyperandrogenism rate was 40.56%. There were statistically significant differences in T, TC, TG, HDL-C and HOMA-IR between abdominal obesity group and non-abdominal obesity group (P<0.05), while there were no statistically significant differences in mF-G score and LDL-C between the two groups (P>0.05). There were statistically significant differences in TC, TG, HDL-C and HOMA-IR between the overall obesity group and the non-overall obesity group (P<0.05), while there were no statistically significant differences in T, mF-G score and LDL-C between the two groups (P>0.05). Pearson correlation analysis showed that WC and BMI were positively correlated with HOMA-IR, TC and TG, but negatively correlated with HDL-C (P<0.05), there was no correlation between LDL-C and LDL-C (P>0.05). There were no significant differences in obesity, HOMA-IR and lipid metabolism between clinical hyperandrogenism group and non-clinical hyperandrogenism group, biochemical hyperandrogenism group and non-biochemical hyperandrogenism group (P>0.05). Multivariate Logistic analysis showed that obesity and IR had no correlation with both biochemical and clinical kaohsiung, and lipid related indexes had no significant correlation with kaohsiung (P>0.05).Conclusion PCOS patients are mainly characterized by abdominal obesity, and abdominal obesity patients are more likely to have glucose and lipid metabolism disorders. Clinical Gaoxiong and biochemical Gaoxiong have the same effect in the diagnosis of PCOS, and whether there is Gaoxiong or not, attention should be paid to IR and lipid metabolism abnormalities to improve the diagnosis and treatment prognosis of PCOS patients.

参考文献/References:

[1]Rotterdam ESHRE/ASRM-Sponsored PCOS consensus workshop group.Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome (PCOS)[J].Hum Reprod,2004,19(1):41-47.[2]Zhao X,Ni R,Li L,et al.Defining hirsutism in Chinese women:across-sectional study[J].Fertil&Steril,2011,96(3):792-796.[3]Matthews DR,Hosker JP,Rudenski AS,et al.Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man[J].Diabetologia,1985,28(7):412-419.[4]Abbasi F,Silvers A,Viren J,et al.Relationship between several surrogate estimates of insulin resistance and a direct measure of insulin mediated glucose disposal:Comparison of fasting versus post glucose load measurements[J].Diabetes Res Clin Pract,2018,136:108-115. [5]Escobar-Morreale HF.Polycystic ovary syndrome:definition,aetiology, diagnosis and treatment[J].Nat Rev Endocrinol,2018,14(5):270-284. [6]Bastard JP,Maachi M,Lagathu C,et al.Recent advances in the relationship between obesity, inflammation, and insulin resistance[J].Eur Cytokine Netw,2006,17(1):4-12.[7]Pasquali R.Metabolic syndrome in polycystic ovary syndrome[J].Front Horm Res,2018,49:114-130. [8]谢应朗,陈发荣,杨敏,等.CT定量测量腹部脂肪面积的研究[J].实用放射学杂志,2000,16(1):43-45.[9]陈丽,兰珍,张丹.不同肥胖标准在评估多囊卵巢综合征胰岛素抵抗中的价值[J].四川大学学报(医学版),2013,44(6):945-949.[10]Diamanti-Kandarakis E,Dunaif A.Insulin resistance and the polycystic ovary syndrome revisited: an update on mechanisms and implications[J].Endocr Rev,2012,33(6):981-1030. [11]Leerasiri P,Wongwananuruk T,Indhavivadhana S,et al.Correlation of clinical and biochemical hyperandrogenism in Thai women with polycystic ovary syndrome[J].J Obstet Gynaecol Res,2016,42(6):678-683.[12]Teede HJ,Misso ML,Costello MF,et al.International PCOS Network. Recommendations from the international evidence-based guideline for the assessment and management of polycystic ovary syndrome[J].Hum Reprod,2018,33(9):1602-1618.[13]Uysal G,Sahin Y,Unluhizarci K,et al.Is acne assign of androgen excess disorder or not[J].Eur J Obstet Gynecol Reprod Biol,2017,211:21-25. [14]朱茜,倪郝,全松.多囊卵巢综合征高雄激素特征及管理[J].中国实用妇科与产科杂志,2019,35(3):274-278.[15]崔琳琳,陈子江.多囊卵巢综合征诊断标准和诊疗指南介绍[J].国际生殖健康/计划生育杂志,2011,30(5):405-408.[16]刘丽,邵洁白,张红萍,等.不同表型多囊卵巢综合征患者的代谢特征[J].全科医学临床与教育,2011,9(5):505-507.[17]Hu H,Kurotani K,Sasaki N,et al.Optimal waist circumference cut-off points and ability of different metabolic syndrome criteria for predicting diabetes in Japanese men and women: Japan Epidemiology Collaboration on Occupational Health[J].Study BMC Public Health,2016,16:220. [18]Williams T,Mortada R,Porter S.Diagnosis and Treatment of Polycystic Ovary Syndrome[J].American Family Physician,2016,94(2):106-113.[19]Gourgari E,Lodish M,Shamburek R,et al.Lipoprotein particles in adolescents and young women with PCOS provide insights into their cardiovascular risk[J].J Clin Endocrinol Metab,2015,100(11):4291-4298.[20]张凤,刘宏伟.多囊卵巢综合征脂类代谢异常及其治疗[J].国际生殖健康/计划生育杂志,2011,30:126-128. [21]Peigné M,Dewailly D.Long term complications of polycystic ovary syndrome (PCOS)[J].Ann Endocrinol,2014,75(4):194-199.

相似文献/References:

[1]袁 奔,潘 伟,罗淑红,等.体重指数对多囊卵巢综合征患者 人工授精妊娠结局影响[J].医学信息,2018,31(12):99.[doi:10.3969/j.issn.1006-1959.2018.12.030]
 YUAN Ben,PAN Wei,LUO Shu-hong,et al.Effects of Body Mass Index on the Outcome of Artificial Insemination in Patients with Polycystic Ovary Syndrome[J].Medical Information,2018,31(12):99.[doi:10.3969/j.issn.1006-1959.2018.12.030]
[2]李德君,李慧君.来曲唑联合苍附导痰汤治疗多囊卵巢综合征不孕症患者的 临床观察[J].医学信息,2018,31(17):137.[doi:10.3969/j.issn.1006-1959.2018.17.043]
 LI De-jun,LI Hui-jun.Clinical Observation of Letrozole Combined with Cangfu Daotan Decoction in the Treatment of Infertility Patients with Polycystic Ovary Syndrome[J].Medical Information,2018,31(12):137.[doi:10.3969/j.issn.1006-1959.2018.17.043]
[3]廖 霜.二甲双胍联合沙格列汀或格列美脲对新诊断合并腹型肥胖的2型糖尿病患者临床疗效对比[J].医学信息,2018,31(24):70.[doi:10.3969/j.issn.1006-1959.2018.24.018]
 LIAO Shuang.Comparison of Clinical Efficacy of Metformin Combined with Salglutin or Glimepiride in Newly Diagnosed Type 2 Diabetic Patients with Abdominal Obesity[J].Medical Information,2018,31(12):70.[doi:10.3969/j.issn.1006-1959.2018.24.018]
[4]曾利文,陈 静,张 晔,等.多囊卵巢综合征患者的糖代谢特点分析[J].医学信息,2019,32(02):103.[doi:10.3969/j.issn.1006-1959.2019.02.029]
 ZENG Li-wen,CHEN Jing,ZHANG Ye,et al.Analysis of Characteristics of Glucose Metabolism in Patients with Polycystic Ovarian Syndrome[J].Medical Information,2019,32(12):103.[doi:10.3969/j.issn.1006-1959.2019.02.029]
[5]谢 丹.不同促排卵方案治疗多囊卵巢综合征不孕症的效果[J].医学信息,2020,33(18):141.[doi:10.3969/j.issn.1006-1959.2020.18.046]
 XIE Dan.The Effect of Different Ovulation Induction Programs on the Infertility of Polycystic Ovary Syndrome[J].Medical Information,2020,33(12):141.[doi:10.3969/j.issn.1006-1959.2020.18.046]
[6]王海燕,毕雪玲,曹 晶,等.坤泰胶囊联合炔雌醇环丙孕酮片、二甲双胍治疗多囊卵巢综合征的效果及对性激素的影响[J].医学信息,2020,33(20):129.[doi:10.3969/j.issn.1006-1959.2020.20.039]
 WANG Hai-yan,BI Xue-ling,CAO Jing,et al.The Effect of Kuntai Capsule Combined with Ethinyl Estradiol and Cyproterone Tablets and Metformin in the Treatment of Polycystic Ovary Syndrome and Its Influence on Sex Hormones[J].Medical Information,2020,33(12):129.[doi:10.3969/j.issn.1006-1959.2020.20.039]
[7]王争艳,宋发荣.中药月经周期疗法治疗PCOS不孕症的效果[J].医学信息,2020,33(20):153.[doi:10.3969/j.issn.1006-1959.2020.20.048]
 WANG Zheng-yan,SONG Fa-rong.The Effect of Chinese Medicine Menstrual Cycle Therapy on PCOS Infertility[J].Medical Information,2020,33(12):153.[doi:10.3969/j.issn.1006-1959.2020.20.048]
[8]朱 艳,周 琴,安 洁,等.脂联素基因单核苷酸多态性与多囊卵巢综合征伴胰岛素抵抗的关系研究[J].医学信息,2020,33(22):87.[doi:10.3969/j.issn.1006-1959.2020.22.025]
 ZHU Yan,ZHOU Qin,AN Jie,et al.Study on the Relationship Between Adiponectin Gene Single Nucleotide Polymorphism and Polycystic Ovary Syndrome with Insulin Resistance[J].Medical Information,2020,33(12):87.[doi:10.3969/j.issn.1006-1959.2020.22.025]
[9]袁 瑞,余亚莉.吡格列酮二甲双胍片治疗胰岛素抵抗型多囊卵巢综合征患者的疗效[J].医学信息,2021,34(01):158.[doi:10.3969/j.issn.1006-1959.2021.01.043]
 YUAN Rui,YU Ya-li.Efficacy of Pioglitazone Hydrochloride and Metformin Hydrochloride Tablets in the Treatment of Patients with Insulin-resistant Polycystic Ovary Syndrome[J].Medical Information,2021,34(12):158.[doi:10.3969/j.issn.1006-1959.2021.01.043]
[10]覃德明,曾 辛,胡雪莉.多囊卵巢综合征患者生殖道微生态状况研究[J].医学信息,2021,34(09):73.[doi:10.3969/j.issn.1006-1959.2021.09.019]
 QIN De-ming,ZENG Xin,HU Xue-li.Study on the Microecological Status of Reproductive Tract in Patients with Polycystic Ovary Syndrome[J].Medical Information,2021,34(12):73.[doi:10.3969/j.issn.1006-1959.2021.09.019]

更新日期/Last Update: 1900-01-01